Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 6/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | HPGDS | O60760 | 2/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | AKT2 | P31751 | 1/20 | 0.43 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439268 | 0.82 | ATR (0.51) | ATRHTTMMP13CYP3A4KMT2A | |
| SCHEMBL441297 | 0.77 | MMP13 (0.54) | ATRHTTHPGDSMMP13CYP3A4 | |
| SCHEMBL439516 | 0.75 | ATR (0.53) | ATRCYP3A4KMT2A | |
| SCHEMBL441253 | 0.74 | HCRTR2 (0.62) | CYP3A4SMN1; SMN2 | |
| SCHEMBL14082168 | 0.72 | MMP13 (0.72) | HTTHPGDSMMP13CYP3A4SMN1; SMN2 | |
| SCHEMBL19028142 | 0.71 | TSHR (0.76) | HTTMMP13CYP3A4KMT2ASMN1; SMN2 | |
| SCHEMBL14082493 | 0.70 | MMP13 (0.79) | HTTMMP13CYP3A4SMN1; SMN2AKT1 | |
| SCHEMBL14082281 | 0.69 | HTT (0.64) | HTTHPGDSMMP13KMT2A | |
| SCHEMBL4775067 | 0.69 | CYP3A4 (0.57) | CYP2A6CYP3A4SMN1; SMN2ADRA2C | |
| SCHEMBL5122215 | 0.69 | HTT (0.57) | HTTHPGDSMMP13CYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY5R | ATR 3803/4885HTT 197/4885HPGDS 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.